DDInter1759 DDInter636
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure.[A1489,A1490] Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Telmisartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) resembles {v} (Compound) Olmesartan
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) resembles {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) resembles {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Olmesartan
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Conjugated estrogens
Conjugated estrogens {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) resembles {v} (Compound) Olmesartan
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) treats {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is palliated by {v} (Compound) Amlodipine
Amlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan {u} (Compound) binds {v} (Gene) PPARG
PPARG {u} (Gene) is downregulated by {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Telmisartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) resembles Candesartan (Compound) and Candesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) resembles Candesartan (Compound) and Candesartan (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is palliated by Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Telmisartan (Compound) binds PPARG (Gene) and PPARG (Gene) is downregulated by Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin